Literature DB >> 2680156

Current approaches to drug therapy for the hypercholesterolemic patient.

J L Witztum1.   

Abstract

CAD is a complex disease with multiple etiologies and aggravating events. Yet, elevated plasma cholesterol levels, chiefly in the form of LDL, are essential for the progression of the atherosclerotic lesion. Any total plasma cholesterol level above an ideal of 180 mg/dl (and an LDL cholesterol level of 100 mg/dl) must be considered atherogenic in the presence of other risk factors. In patients at high risk for death from CAD, combined diet and drug therapy should have as a goal the attainment of ideal lipoprotein values. Drug therapies are now available that make it possible to substantially lower elevated LDL levels in almost all patients and even to achieve ideal levels in those at highest risk.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2680156     DOI: 10.1161/01.cir.80.5.1101

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

1.  Niacin versus niacinamide.

Authors:  A J Mattiussi; D Blais
Journal:  CMAJ       Date:  1992-10-01       Impact factor: 8.262

2.  Cholesterol awareness--key to preventing coronary artery disease.

Authors:  J L Witztum
Journal:  West J Med       Date:  1993-04

Review 3.  Cardiovascular therapies in the 1990s. An overview.

Authors:  R C Becker; J M Gore
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

4.  Colestipol at varying dosage intervals in the treatment of moderate hypercholesterolaemia.

Authors:  D Lyons; J Webster; G Fowler; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of pravastatin.

Authors:  J A Quion; P H Jones
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.